BioNTech SE (BVMF:B1NT34)

BioNTech SE Statistics

Total Valuation

BioNTech SE has a market cap or net worth of BRL 142.24 billion. The enterprise value is 53.50 billion.

Market Cap	142.24B
Enterprise Value	53.50B

Important Dates

The last earnings date was Monday, November 3, 2025.

Earnings Date	Nov 3, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.40%
Shares Change (QoQ)	-1.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	93.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.22
PB Ratio	1.23
P/TBV Ratio	1.36
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-14.97
EV / Sales	2.73
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-17.27

Financial Position

The company has a current ratio of 7.12, with a Debt / Equity ratio of 0.01.

Current Ratio	7.12
Quick Ratio	6.89
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.50
Interest Coverage	-54.07

Financial Efficiency

Return on equity (ROE) is -3.04% and return on invested capital (ROIC) is -2.64%.

Return on Equity (ROE)	-3.04%
Return on Assets (ROA)	-2.30%
Return on Invested Capital (ROIC)	-2.64%
Return on Capital Employed (ROCE)	-4.21%
Revenue Per Employee	2.91M
Profits Per Employee	-527,790
Employee Count	6,772
Asset Turnover	0.14
Inventory Turnover	2.09

Taxes

In the past 12 months, BioNTech SE has paid 308.90 million in taxes.

Income Tax	308.90M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -9.11% in the last 52 weeks. The beta is 1.31, so BioNTech SE's price volatility has been higher than the market average.

Beta (5Y)	1.31
52-Week Price Change	-9.11%
50-Day Moving Average	34.58
200-Day Moving Average	36.82
Relative Strength Index (RSI)	65.76
Average Volume (20 Days)	411

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.04

Income Statement

In the last 12 months, BioNTech SE had revenue of BRL 19.71 billion and -3.57 billion in losses. Loss per share was -14.91.

Revenue	19.71B
Gross Profit	16.26B
Operating Income	-5.04B
Pretax Income	-3.27B
Net Income	-3.57B
EBITDA	-2.93B
EBIT	-5.04B
Loss Per Share	-14.91

Balance Sheet

The company has 90.84 billion in cash and 1.53 billion in debt, giving a net cash position of 89.31 billion.

Cash & Cash Equivalents	90.84B
Total Debt	1.53B
Net Cash	89.31B
Net Cash Per Share	n/a
Equity (Book Value)	115.54B
Book Value Per Share	480.50
Working Capital	85.09B

Cash Flow

In the last 12 months, operating cash flow was -1.98 billion and capital expenditures -1.12 billion, giving a free cash flow of -3.10 billion.

Operating Cash Flow	-1.98B
Capital Expenditures	-1.12B
Free Cash Flow	-3.10B
FCF Per Share	n/a

Margins

Gross margin is 82.49%, with operating and profit margins of -25.55% and -18.13%.

Gross Margin	82.49%
Operating Margin	-25.55%
Pretax Margin	-16.56%
Profit Margin	-18.13%
EBITDA Margin	-14.84%
EBIT Margin	-25.55%
FCF Margin	n/a

Dividends & Yields

BioNTech SE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.40%
Shareholder Yield	0.40%
Earnings Yield	-2.51%
FCF Yield	-2.18%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on November 21, 2022. It was a forward split with a ratio of 2.

Last Split Date	Nov 21, 2022
Split Type	Forward
Split Ratio	2

Scores

BioNTech SE has an Altman Z-Score of 6.95 and a Piotroski F-Score of 2.

Altman Z-Score	6.95
Piotroski F-Score	2